GSK plc (LON:GSK) Insider Hal Barron Sells 19,446 Shares

GSK plc (LON:GSK – Get Free Report) insider Hal Barron sold 19,446 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of GBX 3,462 ($44.17), for a total value of £673,220.52 ($858,918.75).

GSK Trading Up 0.2 %

LON:GSK opened at GBX 1,374 ($17.53) on Friday. The stock has a 50-day simple moving average of GBX 1,367.21 and a 200-day simple moving average of GBX 1,413.77. The stock has a market cap of £56.33 billion, a P/E ratio of 1,083.15, a P/E/G ratio of 0.97 and a beta of 0.31. GSK plc has a 1 year low of GBX 1,280.92 ($16.34) and a 1 year high of GBX 1,609 ($20.53). The company has a debt-to-equity ratio of 176.61, a quick ratio of 0.73 and a current ratio of 0.88.

Get GSK alerts:

GSK Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 17th will be given a dividend of GBX 14 ($0.18) per share. The ex-dividend date is Thursday, August 17th. This represents a dividend yield of 1.01%. GSK’s dividend payout ratio is currently 4,409.45%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,700 ($21.69) price target on shares of GSK in a report on Thursday, June 8th. Jefferies Financial Group restated a “hold” rating and set a GBX 1,575 ($20.09) price target on shares of GSK in a report on Monday, June 26th. JPMorgan Chase & Co. cut their price target on GSK from GBX 1,400 ($17.86) to GBX 1,300 ($16.59) in a report on Tuesday, August 1st. Berenberg Bank restated a “buy” rating and set a GBX 1,730 ($22.07) price target on shares of GSK in a report on Friday, July 28th. Finally, Shore Capital restated a “buy” rating on shares of GSK in a report on Friday, June 16th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of GBX 1,560 ($19.90).

Get Our Latest Report on GSK

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Stories

• Five stocks we like better than GSK
• How to Invest in Small Cap Stocks 
• One of these 5 Pet Care Stocks Can Be the Next Short Squeeze
• What Do S&P 500 Stocks Tell Investors About the Market?
• 3 High Short Interest Stocks that Investors are Getting Wrong
• Special Purpose Acquisition Company (SPAC) What You Need to Know
• Retail Theft Rises: Two Ways For Investors To Beat Shrinkage

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.